TRIAZOLAM
THERAPEUTICS
brands
Class
- Neuroscience-based Nomenclature: GABA positive allosteric modulator (GABA-PAM)
- Benzodiazepine (hypnotic)
TRIAZOLAM commonly prescribed for
(Bold for FDA approved)
How TRIAZOLAM works
• Binds to benzodiazepine receptors at the GABA-A ligand-gated chloride channel complex
• Enhances the inhibitory effects of GABA
• Boosts chloride conductance through GABA-regulated channels
• Inhibitory actions in sleep centers may provide sedative hypnotic effects
How long until TRIAZOLAM works
• Generally takes effect in less than an hour
SIDE EFFECTS
Notable Side Effects
• Sedation, fatigue, depression
• Dizziness, ataxia, slurred speech, weakness
• Forgetfulness, confusion
• Hyperexcitability, nervousness
• Anterograde amnesia
• Rare hallucinations, mania
• Rare hypotension
• Hypersalivation, dry mouth
• Rebound insomnia when withdrawing from long-term treatment
Life Threatening Side Effects
• Respiratory depression, especially when taken with CNS depressants in overdose
• Rare hepatic dysfunction, renal dysfunction, blood dyscrasias
weight gain

unusual
sedation

common
What to do about TRIAZOLAM side effects
• Wait
• To avoid problems with memory, take triazolam only if planning to have a full night’s sleep
• Lower the dose
• Switch to a shorter-acting sedative hypnotic
• Switch to a non-benzodiazepine hypnotic
• Administer flumazenil if side effects are severe or life-threatening
DOSING AND USE
usual dosage range
• 0.125–0.25 mg/day at bedtime for 7–10 days
Dosage Forms
• Tablet 0.125 mg, 0.25 mg
long term use
• Not generally intended for long-term use
• Increased wakefulness during the latter part of the night (wearing off) or an increase in daytime anxiety (rebound) may occur because of short half-life
habit forming
• Triazolam is a Schedule IV drug
• Some patients may develop dependence and/or tolerance; risk may be greater with higher doses
• History of drug addiction may increase risk of dependence
SPECIAL POPULATIONS
Renal Impairment
• Drug should be used with caution
Hepatic Impairment
• Drug should be used with caution
Cardiac Impairment
• Benzodiazepines have been used to treat insomnia associated with acute myocardial infarction
Elderly
• Recommended initial dose: 0.125 mg
• May be more sensitive to adverse effects
Children and Adolescents
• Safety and efficacy have not been established
• Long-term effects of triazolam in children/ adolescents are unknown
• Should generally receive lower doses and be more closely monitored
Pregnancy
• Contraindicated for use in pregnancy
• Effective June 30, 2015, the FDA requires changes to the content and format of pregnancy and lactation information in prescription drug labels, including the elimination of the pregnancy letter categories; the Pregnancy and Lactation Labeling Rule (PLLR or final rule) applies only to prescription drugs and will be phased in gradually for drugs approved on or after June 30, 2001
• Infants whose mothers received a benzodiazepine late in pregnancy may experience withdrawal effects
• Neonatal flaccidity has been reported in infants whose mothers took a benzodiazepine during pregnancy
Breast Feeding
• Unknown if triazolam is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or bottle feed
• Effects on infant have been observed and include feeding difficulties, sedation, and weight loss
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera